A retrospective study on patients with EGFR-sensitive mutant advanced NSCLC treated with EGFR-TKI found that, compared with patients with low pre-treatment serum CRP levels, patients with high pre-treatment serum CRP levels had a significantly poorer response to EGFR-TKI (65, 81).The results suggest that pre-treatment serum CRP levels can independently predict the prognosis of patients with advanced NSCLC who are treated with EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.